

Pathophysiology of Acute Heart Failure

Michael Felker, MD, MHS, FACC
Associate Professor of Medicine
Director of Heart Failure Research




Duke Clinical Research Institute

Disclosures

- Research Support and/or Consulting
 - NHLBI
 - Amgen
 - Cytokinetics
 - Roche Diagnostics
 - Otsuka
 - BG Medicine

Progress in AHF Outcomes




Contemporary Pharmacotherapy for ADHF

1974

- Diuretics
- Vasodilators
- Oxygen
- Consider inotropic therapy

2004




Ramirez, New Engl J Med, 1974

Fonarow, GC et al. AHJ 2007


Underlying Pathophysiology Drives Classification in Acute Coronary Syndromes

Plaque Disruption/Fissure/Erosion


Thrombus Formation



UA



NQMI



STE-MI

Old Terminology:

New Terminology:

Non-ST-Segment Elevation Acute Coronary Syndrome (ACS)

ST-Segment Elevation Acute Coronary Syndrome (ACS)

What is the “thrombus” of AHF?

ACS

AHF

“The most common cause of UA/NSTEMI is reduced myocardial perfusion that results from coronary artery narrowing caused by a nonocclusive thrombus that developed on a disrupted atherosclerotic plaque and is usually nonocclusive.”

AHA/ACC Guidelines

????????????????????


Will greater insight into pathophysiology lead to better therapies?

A Fundamental Issue: Are These Patients the Same or Different?

60 yo man with long history of HF

3 weeks of gradually worsening symptoms



BP 85/40



80 yo woman with long history of HTN

1 hour of sudden onset of symptoms

BP 185/120



Old Paradigms:

- Acute MI is just a worsening of chronic angina that needs to be treated with bed rest and morphine until people feel better and can go home
- Acute HF is just a worsening of chronic HF that needs to be treated with bed rest and diuretics until people feel better and can go home


AHF is More Complex than We Think

AHF as a volume overload disorder



AHF as a cardio-renal-vascular-inflammatory disorder

Schematic of Pathophysiology of AHF




Pathophysiology of ADHF

- Initiating factors/triggers
- Congestion
- Myocardial injury
- Renal mechanisms
- Vascular mechanisms

Key Precipitants:


- Non-compliance
- Poorly controlled HTN
- Ischemia/ACS
- Afib or other arrhythmias
- Infections
- Pulmonary emboli
- Worsening renal function

Different Precipitants Lead to Different Risk




Symptoms: The Tip of the Congestion Iceberg in Heart Failure


S
Y
M
P
T
O
M
S




Elevated Filling Pressures Precede Hospitalization




Chronic Congestion Predisposes to AHF




Congestion is both Cause and Effect



Troponin I and In-hospital Mortality in ADHF



Mechanism of Cardiac Troponin Release in Heart Failure




Questions about Myocardial Injury in AHF

- Cause or effect?
- Time course?
 - Pre-hospital
 - In-hospital
- What can we do to prevent or ameliorate it?
- What should we do when it is present?


Renal Function as a Risk Marker in ADHF

Multicenter, retrospective chart review of 1002 patients




Effect of Worsening Renal Function on Outcomes in Patients With Acute Heart Failure

HF Hospitalizations and Cardiovascular Mortality-Free Survival




The Cardiorenal Syndrome of Heart Failure




BUN and Creatinine are Late Biomarkers of AKI

Biomarkers




Congestion Drives Worsening Renal Function



“Vascular” Mechanisms in Acute Heart Failure


- Hypertension (not hypotension) is the norm in AHF
 - ADHERE =143 mmHg, OPTIMIZE=143 mmHg
 - Pre-hospital community registry w mean SBP=168 mmHg
- “Vascular HF” related to afterload-contractility mismatch?
 - Increase LVEDP despite modest or no volume overload
 - “Volume redistribution” rather than “volume overload”

SBP in AHF: Higher is Better?




Rapid Dyspnea Improvement through 24 hours (Likert Scale)

Proportion of Patients with Moderate/Marked
Improvement in Dyspnea at 6, 12 and 24 hr




Pharmacologic Actions of hBNP



Which BNP are you Talking About?

The Choices are Multiplying



The BNP Paradox: My Patient has a BNP >500— Why isn't all the BNP Doing Him Any Good?

- Available assays for NTproBNP and BNP are influenced by HMW forms
- Experimental assays for proBNP suggest proBNP may be primary circulating form in some patients with advanced heart failure
- ProBNP less biologically active (~ 8 fold difference) than BNP--? “defective” BNP in some patients with HF?

Conclusions

- Pathophysiology of AHF is
 - Complex
 - Heterogeneous
 - Poorly understood
- Better understanding of the interaction between specific treatments and specific mechanisms will be key to success moving forward